CRGX(Delisted)
CARGO Therapeutics·NASDAQ
--
--(--)
CARGO Therapeutics (CRGX) Financial Statements
CARGO Therapeutics (CRGX) Income Statement
During Q3 2024, CARGO Therapeutics (CRGX) reported revenue of --, a YoY change of 0.00%. Net income was -41.91M, a YoY change of -18.15%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | TTM |
|---|
Start Date | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | -- |
End Date | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Operating Expenses | 10.05M -- | 11.01M -- | 15.25M -- | 17.80M -- | 28.71M +185.71% | 34.96M +217.64% | 40.81M +167.63% | 49.32M +177.13% | 47.11M +64.09% | 172.19M -- |
Selling, General and Administrative Expenses | 1.58M -- | 1.77M -- | 2.69M -- | 3.87M -- | 6.48M +310.00% | 7.89M +344.70% | 10.30M +283.72% | 11.86M +206.70% | 11.18M +72.58% | 41.23M -- |
Research and Development Expenses | 8.47M -- | 9.23M -- | 12.56M -- | 13.93M -- | 22.23M +162.52% | 27.07M +193.22% | 30.50M +142.82% | 37.46M +168.92% | 35.93M +61.62% | 130.96M -- |
Operating Income | -10.05M -- | -11.01M -- | -15.25M -- | -17.80M -- | -28.71M -185.71% | -34.96M -217.64% | -40.81M -167.63% | -49.32M -177.13% | -47.11M -64.09% | -172.19M -- |
Non-Operating Income (Loss) | -2.24M -- | -2.74M -- | 2.50M -- | -56.00K -- | -6.76M -202.33% | 2.88M +204.92% | 5.00M +99.80% | 4.97M +8975.00% | 5.20M +176.98% | 18.05M -- |
Other Non-Operating Income (Loss) | -778.00K -- | -36.00K -- | 4.00M -- | -634.00K -- | -7.65M -883.80% | 4.46M +12477.78% | -10.00K -100.25% | -17.00K +97.32% | -199.00K +97.40% | 4.23M -- |
Net Interest Expense | 1.46M -- | 2.71M -- | 1.50M -- | -578.00K -- | -894.00K -161.32% | 1.58M -41.77% | -5.00M -433.89% | -4.99M -762.80% | -5.40M -504.36% | -13.82M -- |
Interest Expense | 1.46M -- | 2.71M -- | 1.60M -- | -- -- | -- -- | 0 -100.00% | -- -- | -- -- | -- -- | -- -- |
Interest Income | -- -- | -- -- | 105.00K -- | 578.00K -- | 894.00K -- | -1.58M -- | 5.00M +4666.67% | 4.99M +762.80% | 5.40M +504.36% | 13.82M -- |
Pretax Income From Continuing Operations | -12.29M -- | -13.75M -- | -12.75M -- | -17.85M -- | -35.47M -188.73% | -32.08M -133.30% | -35.81M -180.94% | -44.35M -148.42% | -41.91M -18.15% | -154.14M -- |
Net Income from Continuing Operations | -12.29M -- | -13.75M -- | -12.75M -- | -17.85M -- | -35.47M -188.73% | -32.08M -133.30% | -35.81M -180.94% | -44.35M -148.42% | -41.91M -18.15% | -154.14M -- |
Net Income | -12.29M -- | -13.75M -- | -12.75M -- | -17.85M -- | -35.47M -188.73% | -32.08M -133.30% | -35.81M -180.94% | -44.35M -148.42% | -41.91M -18.15% | -154.14M -- |
Net Income Attributable to Owners of the Company | -12.29M -- | -13.75M -- | -12.75M -- | -17.85M -- | -35.47M -188.73% | -32.08M -133.30% | -35.81M -180.94% | -44.35M -148.42% | -41.91M -18.15% | -154.14M -- |
Net Income Attributable to Common Stockholders | -12.29M -- | -13.75M -- | -12.75M -- | -17.85M -- | -35.47M -188.73% | -32.08M -133.30% | -35.81M -180.94% | -44.35M -148.42% | -41.91M -18.15% | -154.14M -- |
Other Comprehensive Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -279.00K -- | -44.00K -- | 958.00K -- | -- -- |
Total Comprehensive Income | -12.29M -- | -13.75M -- | -12.75M -- | -17.85M -- | -35.47M -188.73% | -32.08M -133.30% | -36.09M -183.13% | -44.39M -148.67% | -40.95M -15.45% | -153.51M -- |
Total Comprehensive Income Attributable to Owners of the Company | -12.29M -- | -13.75M -- | -12.75M -- | -17.85M -- | -35.47M -188.73% | -32.08M -133.30% | -36.09M -183.13% | -44.39M -148.67% | -40.95M -15.45% | -153.51M -- |
You can ask Aime
No Data
